March 9, 2023
The Japanese health ministry on March 8 announced the results of price adjustments based on cost-effectiveness assessments (CEAs) for nine APIs including Eli Lilly’s migraine med Emgality (galcanezumab) and Gilead Sciences’ Veklury (remdesivir). New prices will take effect on June...read more